Last week’s JPM 2026 marked a clear inflection point for the life sciences sector. After several years defined by a “biotech winter,” constrained capital markets, and muted deal activity, the mood in San Fran was optimistic. The second half of 2025 brought renewed confidence and the week showed reflected how healthcare is ready to move from reset to reacceleration. Public markets showed early signs of reopening, biotech equities rebounded, and both strategics and investors signaled a willingness to engage again, albeit with greater discipline.

One of the most notable shifts this year was how dealmaking showed up. Large pharmas reiterated their appetite for best-in-class and first-in-class assets as patent cliffs loom, emphasizing partnerships, licensing, and targeted acquisitions over headline-driven deals. The takeaway was clear: dealmaking hasn’t slowed, it’s simply become more intentional and less performative.

AI also continued its evolution from buzzword to backbone. AI was discussed organically as an integrated part of drug discovery, clinical development, and even wet-lab automation. Major collaborations underscored the scale of investment flowing into AI-enabled biology, while real clinical validation began to emerge, reinforcing that the technology is moving beyond promise toward proof. The conversation has shifted from whether AI matters to what it’s actually delivering.

China’s growing influence in global biotech was another theme. China is now producing truly novel assets across oncology, cardiometabolic, inflammatory, and rare diseases with faster, cheaper clinical pathways accelerating progress. While this presents clear partnership opportunities, it has also intensified concerns about regulatory competitiveness in the U.S. and Europe, particularly as trade policy, research funding, and immigration constraints risk slowing Western innovation at a pivotal moment.

Finally, JPM 2026 highlighted a new wave of therapeutic momentum. Radiopharmaceuticals emerged as one of the most closely watched frontiers in oncology, following early IPO activity and increasing pharma engagement. At the same time, excitement is building around siRNA, cell and gene therapies for autoimmune and neurodegenerative diseases, xenotransplantation, and even psychedelics in neurology. Collectively, these trends signal that the next chapter of biotech innovation is broadening, globalizing, and increasingly aligned with earlier intervention and durable patient outcomes.